Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Under the Laberwork	neduction Act of 1995, no p	ersons a	re required to respond to a c	offection of information unless it contain	s a valid OMB control number.	
	Substitute for form 1449/PTO			Complete if Known		
STATEMENT BY APPLICANT  Date Submitted: April 14 2008				Application Number	09/506,011	
				Filing Date	02/17/2000	
				First Named Inventor	John Cooper COX	
				Art Unit	1648	
(use as many sheets as necessary)			sary)	Examiner Name	Emily M. Le	
Sheet	1	of	1	Attorney Docket Number	017227-0155	

U.S. PATENT DOCUMENTS					
	Cite	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	No.1	Number-Kind Code <sup>2</sup> ( <i>if known</i> )			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code <sup>3</sup> ·Number <sup>4</sup> ·Kind Code <sup>5</sup> (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sub>6</sub>

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	<b>T</b> 6
	C1	Mark A. RIGBY et al., "Immunogenicity of a peptide from a major neutralising determinant of the feline immunodeficiency virus surface glycoprotein", Vaccine, Vol. 14, No. 12, pp. 1095—1102, 1996.	
	C2	Database entry: BIOSIS PREV199799800835: A. AHLUMWALIEA et al., "Modification of delivery system enhances MHC nonresistricted immunogenicity of V3 loop region of HIV-1 gp120", MICROBIOLOGY & IMMUNOLOGY 1997, vol. 41, no. 10, **ABSTRACT.	
	C3	Grayson B. LIPFORD et al., "Vaccination with immunodominant peptides encapsulated in Quil A-containing liposomes induces peptide-specific primary CD8+ cytotoxic T cells", Vaccine 1994, Vol. 12, No. 1, pp. 73—80.	

Examiner Signature	Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.